Request a Quote

Cyprotex Highlights - September 2022

2022 Header

Catch up with our blog this month as we review ICH M12 and how these draft guidelines compare with other regulatory guidance for in vitro DDI studies.

Read about ICH M12

We travelled to Maastricht in the Netherlands for the 16th International Congress of Toxicology (ICT).

While there, our expert Alicia Rosell-Hidalgo PhD presented our latest research with the poster 'High-content screening and high-throughput RNA sequencing using hiPSC-CMs for the assessment of functional and structural cardiotoxicity'.

Find out more by reading our blog and downloading the poster:

Read the blog

Read the poster

Read the latest news from parent company, Evotec:

  • Project from Dundee University is awarded funding from Evotec's translational BRIDGE beLAB1407 initiative
  • Partnership between Just – Evotec Biologics and Alpine Immune Sciences is expanded to include commercial process development of ALPN 303
  • PAN-TB collaboration supports the progression of two investigational tuberculosis drug regimens to phase 2 clinical development
  • Evotec wins 2022 R&D 100 Award for EVOpanHunter
  • Evotec acquires Central Glass Germany to expand clinical and commercial drug substance manufacturing
  • Evotec launches construction of new J.POD® biologics facility in Toulouse, France
  • U.S. Department of Defense awards contract to Just – Evotec Biologics under accelerated antibodies program

Read the press releases

Read more from Evotec, Cyprotex and Just - Evotec Biologics in the Science Pool blog:

Read the blog

Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683

or fill out the form below:


Download file